Your unfiltered news center. ®
The world you see depends upon the news you get. ®
Powered By: BlackRadioNetwork.com | MinorityNewsService.net | MinorityNews.net
Today's Date: September 25, 2023
2023 GLOBAL CITIZEN FESTIVAL SEES $240 MILLION COMMITMENT FROM FRANCE AND NORWAY TO COMBAT THE GLOBAL FOOD CRISIS
• France Announces €40 Million in New Funding to Education Cannot Wait at Global Citizen Festival
• 65+ Populations in Upstate NY's 4 Largest Regions Surging, Getting Poorer; AARP NY to Meet with Local Leaders
• A Meyers Manx Collaboration with Artist Sage Vaughn Contributes $200,000 to Arts Education Fundraiser
• No more oil, gas and coal. Two nation-states join growing bloc of countries calling for a Fossil Fuel Non-Proliferation Treaty
• Statement by the Prime Minister on Yom Kippur
• Statement by Minister Khera on Yom Kippur
• Guidewire Optimistic About New Direction of California Insurance
• Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo • Wondershare FamiSafe 7.0 safeguarding Children with AI
• 2023 Gangnam Festival to be Held in Gangnam, the Heart of K-pop
• Sixth Annual War Heroes on Water Charity Sportfishing Tournament Kicks Off, Bringing Hope and Healing to Combat-Wounded Veterans • Unitedprint.com collaborates with Pexels.com
• Intel Editorial: Intel Addresses Semiconductor Workforce Shortage
• Joint Statement on the Importance of Comprehensive, Multidisciplinary and Collaborative Care for Patients with Peripheral Artery • PRAIRIE VIEW A&M UNIVERSITY ANNOUNCES 2023-2024 WRITER-IN-RESIDENCE ATTICA LOCKE
• THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON
• Shift4 Partners with Give Lively to Offer Powerful Fundraising Solution to Nonprofits
• Student Entrepreneurs from Yale University Win Prestigious $1 Million 2023 Hult Prize
• Reactive Technologies’ Grid Inertia Measurement Tech to Enable Offshore Wind Rollout in Taiwan
Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipili
PRINCETON, N.J. , June 04 /Businesswire/ - $BMY announces four-year data to be presented at #ASCO23 from Phase 3 trial with dual immunotherapy-based combination in metastatic non-small cell #lungcancer. #LCSM
LIVE VIDEO EVERY SATURDAY
LIVE BROADCASTS
Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
Los Angeles - KJLH - Urban
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
New York - WBAI - Progressive
Washington - WOL-Urban
